Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. van Meerbeeck (Edegem, Belgium), D. De Ruysscher (Maastricht, Netherlands), J. Belderbos (Amsterdam, Netherlands), K. De Jaeger (Eindhoven, Netherlands), F. Koppe (Tilburg, Netherlands), M. Lambrechts (Leuven, Belgium), Y. Lievens (Ghent, Belgium), E. Dieleman (Amsterdam, Netherlands), J. Jaspers (Rotterdam, Netherlands), J. Ubbels (Groningen, Netherlands), M. Kwint (Maastricht, Netherlands), M. Kuenen (Amsterdam, Netherlands), S. Deprez (Leuven, Belgium), M. De Ruiter (Amsterdam, Netherlands), K. Sikorska (Amsterdam, Netherlands), H. Van Tinteren (Amsterdam, Netherlands), S. Schagen (Amsterdam, Netherlands). Neuro-cognitive (HVLT-R total recall) functioning in localized vs. metastatic small-cell lung cancer with or without hippocampus sparing PCI: Results from a phase III trial. 5103

Member's Comments

No comment yet.

Related content which might interest you: Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003 A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Symptom control in advanced non-small cell lung cancer (NSCLC): what is the influence of cisplatin-use, age, performance status and duration of chemotherapy? Analysis of a randomized database Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors Year: 2008 LATE-BREAKING ABSTRACT: Triplet chemotherapy (paclitaxel/gemcitabine/cisplatin) is more active in advanced squamous cell subtype (SCC) non-small cell lung cancer (NSCLC) than doublet treatment (vinorelbine/cisplatin): A randomized phase III trial in 443 NSCLC patients Source: Annual Congress 2012 - Diagnosis and biology of malignant pleural effusions Year: 2012 A three-arm phase III randomised trial assessing, in patients with extensive-disease (ED) small-cell lung cancer (SCLC), accelerated chemotherapy with the support of haematological growth factor or of oral antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 319s Year: 2001 Systematic review of the effect of chemotherapy on quality of life (QoL) and symptom control in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 A randomised phase III comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002 Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Efficacy of a pulmonary rehabilitation programme (PRP) after lung resection (LR) for cancer Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention Year: 2005 Stage I-IIIa small cell lung cancer (SCLC): multimodal therapy including surgery Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001 Early versus late pulmonary rehabilitation (PR) following treatment for inoperable nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2013 –The best abstracts in extra-pulmonary features and pulmonary rehabilitation Year: 2013 Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 A multicenter phase II study of carboplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) in elderly patients (GFPC 9902) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002 Treatment of early (stage I/II) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Phase II study of S-1 with patient-reported outcome evaluation in elderly patients with previously untreated advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S) Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002